Changsen Pharmaceutical has successfully closed a multi-billion RMB Series B+ financing round led by Qiming Venture Partners, aimed at advancing its innovative drug development and global strategic expansion.

Target Company Overview

Recently, Shanghai Changsen Pharmaceutical Co., Ltd. (referred to as "Changsen Pharmaceutical") announced the successful completion of a multi-billion RMB Series B+ financing round, led by Qiming Venture Partners. The funds raised will primarily be allocated to advancing critical clinical research of its core pipeline and establishing a global footprint.

Changsen Pharmaceutical was founded in 2012 by Dr. Wang Zhe, a globally recognized expert in chemical drug development. The company focuses on the independent research and development of First-in-Class (FIC) and Best-in-Class (BIC, next-generation) innovative drug products with global intellectual property rights, aiming to address unmet clinical needs. With nearly 100 invention patents, Changsen has been recognized as a "Specialized, Refinement, Distinctive, and Innovative" enterprise by the Shanghai government and is engaged in several major projects sponsored by the Ministry of Science and Technology and the municipal government.

Industry Overview in China

China's pharmaceutical industry has been undergoing rapid transformation, driven by increasing demand for innovative therapies and a focus on improving healthcare standards. The government has prioritized the development of the biopharmaceutical sector, implementing